Latest Safety News

Carawine Resources has updated the market with its December 2024 quarterly report, highlighting exploration progress in the Paterson province and an impending court hearing over a compulsory acquisition by major shareholder QGold.

Citigold Corporation reports steady progress in restarting its Charters Towers Gold Project, highlighting successful test mining and ongoing exploration while preparing for large-scale production.

Element 25 Limited reports a transformative quarter with a 142% resource increase at Butcherbird, a compelling $561 million NPV feasibility study, and a $268 million US Department of Energy grant to advance its Louisiana battery-grade manganese refinery.

Karoon Energy delivered a record full-year sales revenue of US$776.5 million in 2024 despite a slight production dip in the final quarter. The company’s revised resource estimates and plans to acquire the Baúna FPSO signal a pivotal phase for its growth trajectory.

Latrobe Magnesium marks a year without lost time injuries and completes key construction phases, while navigating legal disputes and operational cost pressures.

Argenica Therapeutics has dosed 80% of patients in its Phase 2 stroke trial and gained FDA orphan drug designations for its second candidate, ARG-006. The company reports a cash-positive quarter with $15 million in reserves.

Tryptamine Therapeutics has reported successful Phase 1b results for its IV-infused psilocin candidate TRP-8803 and promising interim data for oral psilocybin TRP-8802 in IBS treatment, while securing $6 million in new funding to accelerate clinical development.

Alterity Therapeutics has announced encouraging Phase 2 trial results for ATH434, showing significant slowing of disease progression in multiple system atrophy (MSA) patients and a strong safety profile. These findings mark a potential breakthrough in treating a disease with no approved therapies.

Argenica Therapeutics has received a positive safety review from its independent DSMB for the Phase 2 trial of ARG-007 in acute ischaemic stroke patients, with dosing now 86% complete and full recruitment expected by early Q2 2025.

Syrah Resources faces significant operational disruption at its Balama graphite mine due to ongoing protests, declaring force majeure while advancing its US-based Vidalia facility amid strong EV market growth.

IGO's December quarter report reveals robust performance at Greenbushes lithium mine but significant setbacks at Kwinana and Nova, culminating in a $79 million EBITDA loss and a strategic halt on Kwinana’s Plant 2.

NeuroScientific Biopharmaceuticals has initiated critical IND-enabling studies for its glaucoma drug candidate EmtinB, backed by a solid cash position of A$4.5 million as of December 2024. Preliminary melanin binding results are shaping the path toward first-in-human trials.